Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۵۰۰ • واحد: mg/L
حداقل ۱۰ — حداکثر ۶۰ • واحد: g/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Score 00–0
- Score 11–1
- Score 22–2
The Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include crp level. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Provides improved cancer prognosis over the original Glasgow Prognostic Score, based on serum biomarkers (CRP and albumin) reflecting systemic inflammation and nutritional status
Clinical Indication
The Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes is indicated for bedside clinical practice to support Provides improved cancer prognosis over the original Glasgow Prognostic Score, based on serum biomarkers (CRP and albumin) reflecting systemic inflammation and nutritional status. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Should be interpreted in context of cancer stage, treatment status, and other prognostic factors.
Score determined by CRP and albumin levels. Score 0: CRP ≤10 mg/L (any albumin). Score 1: CRP >10 mg/L and albumin ≥35 g/L. Score 2: CRP >10 mg/L and albumin <35 g/L.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| crp_level | float | Yes | C-Reactive Protein (CRP) level(mg/L) |
| albumin_level | float | Yes | Serum albumin level(g/L) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Score 0 | Good prognosis |
| 1–1 | Score 1 | Intermediate prognosis |
| 2–2 | Score 2 | Poor prognosis |
Evidence-Based References (EBM)
- Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, Horgan PG, McMillan DC. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011 Aug 23;105(5):726-34. doi: 10.1038/bjc.2011.292.DOI: 10.1038/bjc.2011.292
- McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013 Aug;39(5):534-40. doi: 10.1016/j.ctrv.2012.08.003.DOI: 10.1016/j.ctrv.2012.08.003
- Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003 Aug 4;89(3):477-81. doi: 10.1038/sj.bjc.6601242.DOI: 10.1038/sj.bjc.6601242